StreetInsider

• Log in to your account:

  
  Log in
• Signup
• Home
• EPS Insider
• Event Calendar
• Conferences
• Classic Site

Upgrade to SI Premium - Free Trial

Gilead Sciences (GILD)

Form 4 GILEAD SCIENCES, INC. For: Sep 10 Filed by: Dickinson Andrew D September 11, 2026 6:31 PM - SEC Filing Form 4 GILEAD SCIENCES, INC. For: Sep 10 Filed by: Berger Dietmar September 11, 2026 6:30 PM - SEC Filing Form 4 GILEAD SCIENCES, INC. For: Sep 10 Filed by: Mercier Johanna September 11, 2026 6:29 PM - SEC Filing Form 4 GILEAD SCIENCES, INC. For: Sep 10 Filed by: Cain Wettan Keeley M September 11, 2026 6:28 PM - SEC Filing Form 4 GILEAD SCIENCES, INC. For: Sep 10 Filed by: O'Day Daniel Patrick September 11, 2026 6:27 PM - SEC Filing Gilead Sciences (GILD) PT Raised to $175 at HSBC September 10, 2026 3:28 AM - StreetInsider Assembly Bio exercises U.S. profit-share option with Gilead for herpes program September 8, 2026 4:00 PM - StreetInsider Form 4 GILEAD SCIENCES, INC. For: Aug 26 Filed by: WELTERS ANTHONY August 27, 2026 6:45 PM - SEC Filing FDA approves Gilead's Bixlenvo HIV tablet for adults on complex regimens August 27, 2026 5:47 PM - StreetInsider U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens August 27, 2026 5:47 PM - BizWire Form 144 GILEAD SCIENCES, INC. Filed by: WELTERS ANTHONY August 26, 2026 4:17 PM - SEC Filing Form N-PX GILEAD SCIENCES, INC. For: Jun 30 August 26, 2026 4:15 PM - SEC Filing Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences August 26, 2026 4:05 PM - BizWire EU approves Gilead's Trodelvy combo with Keytruda for front-line TNBC August 24, 2026 6:31 AM - StreetInsider European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status August 24, 2026 6:31 AM - BizWire Form 4 GILEAD SCIENCES, INC. For: Aug 20 Filed by: Bluestone Jeffrey August 21, 2026 7:22 PM - SEC Filing Form 144 GILEAD SCIENCES, INC. Filed by: Bluestone Jeffrey August 20, 2026 4:36 PM - SEC Filing Form 4 GILEAD SCIENCES, INC. For: Aug 17 Filed by: Dickinson Andrew D August 18, 2026 7:06 PM - SEC Filing Form 4 GILEAD SCIENCES, INC. For: Aug 17 Filed by: Mercier Johanna August 18, 2026 6:54 PM - SEC Filing Form 144 GILEAD SCIENCES, INC. Filed by: Mercier Johanna August 17, 2026 4:19 PM - SEC Filing Form 144 GILEAD SCIENCES, INC. Filed by: Dickinson Andrew D August 17, 2026 4:12 PM - SEC Filing Form 4 GILEAD SCIENCES, INC. For: Aug 10 Filed by: Cain Wettan Keeley M August 11, 2026 4:51 PM - SEC Filing Morgan Stanley tracks US drug market prescriptions for week ending July 31 August 7, 2026 12:04 PM - StreetInsider Form S-3ASR GILEAD SCIENCES, INC. August 6, 2026 5:04 PM - SEC Filing Form 10-Q GILEAD SCIENCES, INC. For: Jun 30 August 6, 2026 4:19 PM - SEC Filing Gilead Sciences (GILD) PT Raised to $123 at RBC Capital August 5, 2026 7:48 AM - StreetInsider CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results August 4, 2026 9:41 PM - BizWire Form 4 GILEAD SCIENCES, INC. For: Aug 03 Filed by: O'Day Daniel Patrick August 4, 2026 5:41 PM - SEC Filing Gilead Sciences (GILD) Tops Q2 EPS by 56c August 4, 2026 4:33 PM - StreetInsider Form 8-K GILEAD SCIENCES, INC. For: Aug 04 August 4, 2026 4:04 PM - SEC Filing Gilead Sciences Announces Second Quarter 2026 Financial Results August 4, 2026 4:01 PM - BizWire Gilead Sciences (GILD) call put ratio 1 call to 1.1 puts into quarter results August 4, 2026 10:46 AM - StreetInsider Form 144 GILEAD SCIENCES, INC. Filed by: O'Day Daniel Patrick August 3, 2026 4:42 PM - SEC Filing Form 13F-HR GILEAD SCIENCES, INC. For: Jun 30 August 3, 2026 4:38 PM - SEC Filing Gilead Sciences (GILD) call put ratio 3.2 calls to 1 put into quarter results August 3, 2026 10:53 AM - StreetInsider Gilead Sciences (GILD) call put ratio 1.8 calls to 1 put into quarter results August 3, 2026 6:03 AM - StreetInsider U.S. biopharma earnings: Eli Lilly (LLY), Pfizer (PFE) take the stage August 1, 2026 10:00 AM - StreetInsider Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD) Following Q2 Print July 29, 2026 9:27 AM - StreetInsider Gilead Sciences (GILD) PT Lowered to $145 at Barclays July 29, 2026 5:19 AM - StreetInsider Gilead Sciences (GILD) PT Lowered to $165 at Morgan Stanley July 27, 2026 7:56 AM - StreetInsider EU panel backs Gilead's Trodelvy plus Keytruda for breast cancer July 24, 2026 6:26 AM - StreetInsider CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer July 24, 2026 6:26 AM - BizWire Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 July 21, 2026 4:05 PM - BizWire Gilead to present lenacapavir HIV trial data at AIDS 2026 July 21, 2026 10:00 AM - StreetInsider Gilead and Merck HIV pill shows strong results in Phase 3 trials July 21, 2026 10:00 AM - StreetInsider Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure July 21, 2026 10:00 AM - BizWire Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy July 21, 2026 10:00 AM - BizWire Leerink Downgrades Gilead Sciences (GILD) to Market Perform July 20, 2026 4:17 PM - StreetInsider Form 4 GILEAD SCIENCES, INC. For: Jul 15 Filed by: Dickinson Andrew D July 16, 2026 6:08 PM - SEC Filing Form 4 GILEAD SCIENCES, INC. For: Jul 15 Filed by: Mercier Johanna July 16, 2026 4:55 PM - SEC Filing Form 144 GILEAD SCIENCES, INC. Filed by: Mercier Johanna July 15, 2026 4:13 PM - SEC Filing Form 144 GILEAD SCIENCES, INC. Filed by: Dickinson Andrew D July 15, 2026 4:11 PM - SEC Filing Gilead Sciences (GILD) PT Lowered to $166 at Morgan Stanley July 8, 2026 8:08 AM - StreetInsider Gilead Sciences (GILD) PT Lowered to $120 at RBC Capital July 7, 2026 7:55 AM - StreetInsider Gilead Sciences (GILD) PT Lowered to $156 at Truist Securities July 7, 2026 7:09 AM - StreetInsider HSBC Upgrades Gilead Sciences (GILD) to Buy July 6, 2026 1:35 AM - StreetInsider Form 4 GILEAD SCIENCES, INC. For: Jul 01 Filed by: O'Day Daniel Patrick July 2, 2026 4:14 PM - SEC Filing FDA clears Gilead's Trodelvy for first-line metastatic TNBC June 24, 2026 4:29 PM - StreetInsider U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer June 24, 2026 4:29 PM - BizWire Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market June 24, 2026 8:30 AM - StreetInsider EU approves Gilead's Trodelvy for first-line metastatic TNBC June 23, 2026 7:45 AM - StreetInsider European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors June 23, 2026 7:45 AM - BizWire Gilead Sciences (GILD) Reiterated at Overweight by Cantor Fitzgerald: Yeztugo Total TRx Down June 22, 2026 7:39 AM - StreetInsider Gilead Sciences (GILD) Reiterated at Overweight by Cantor Fitzgerald post CFO Chat June 17, 2026 6:54 AM - StreetInsider Form 4 GILEAD SCIENCES, INC. For: Jun 15 Filed by: Mercier Johanna June 16, 2026 6:02 PM - SEC Filing Form 4 GILEAD SCIENCES, INC. For: Jun 15 Filed by: Dickinson Andrew D June 16, 2026 5:53 PM - SEC Filing Gilead Sciences (GILD) Reiterated at Overweight by Cantor Fitzgerald on FDA Approval June 16, 2026 7:05 AM - StreetInsider Full Article List